TY - JOUR
T1 - Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma
T2 - A Nationwide Cohort Study
AU - van der Kooij, Monique K.
AU - Dekkers, Olaf M.
AU - Aarts, Maureen J. B.
AU - van den Berkmortel, Franchette W. P. J.
AU - Boers-Sonderen, Marye J.
AU - de Groot, Jan Willem B.
AU - Hospers, Geke A. P.
AU - Piersma, Djura
AU - van Rijn, Rozemarijn S.
AU - Suijkerbuijk, Karijn P. M.
AU - Westgeest, Hans M.
AU - van der Veldt, Astrid A. M.
AU - Vreugdenhil, Gerard
AU - Wilgenhof, Sofie
AU - Wouters, Michel W. J. M.
AU - Haanen, John B. A. G.
AU - van den Eertwegh, Alfonsus J. M.
AU - Kapiteijn, Ellen
PY - 2021/9
Y1 - 2021/9
N2 - Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients >= 60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.
AB - Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients >= 60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.
KW - sex
KW - advanced melanoma
KW - immunotherapy
KW - targeted therapy
KW - prospective nation-wide data
KW - CLINICOPATHOLOGICAL FEATURES
KW - EUROPEAN ORGANIZATION
KW - POOLED ANALYSIS
KW - SURVIVAL
KW - BRAF
KW - STAGE
KW - EXPRESSION
U2 - 10.3390/cancers13184639
DO - 10.3390/cancers13184639
M3 - Article
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 18
M1 - 4639
ER -